PepGen Inc. (PEPG) stock
PEPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.88−0.31 (-7.40%)
Close on Nov 17, 2026Market cap $268.73MP/E –Yield –
PepGen operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
PepGen's operating income for the twelve months ending Jun 30, 2026 was -$76.24M. For fiscal 2025 it was -$93.61M. The highest annual figure on record is -$27.11M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$93.61M | – |
| FY2024 | Dec 31, 2024 | -$97.74M | – |
| FY2023 | Dec 31, 2023 | -$84.77M | – |
| FY2022 | Dec 31, 2022 | -$68.30M | – |
| FY2021 | Dec 31, 2021 | -$27.11M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.94M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.94M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.71M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.65M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.93M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.32M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.43M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.81M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$21.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$17.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$19.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.64M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.89M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.19M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.63M | – |
See a number that looks wrong?